Hostname: page-component-74656f9884-j7cmm Total loading time: 0 Render date: 2026-11-09T04:36:26.691Z Has data issue: false hasContentIssue false

The utility and sustainability of US Ebola treatment centers during the coronavirus disease 2019 (COVID-19) pandemic

Published online by Cambridge University Press:  22 February 2022

Jocelyn J. Herstein*
Affiliation:
University of Nebraska Medical Center, Omaha, Nebraska
Paul D. Biddinger
Affiliation:
Massachusetts General Hospital, Boston, Massachusetts
Shawn G. Gibbs
Affiliation:
Texas A&M University, College Station, Texas
Angela L. Hewlett
Affiliation:
University of Nebraska Medical Center, Omaha, Nebraska Nebraska Medicine, Omaha, Nebraska
Aurora B. Le
Affiliation:
University of Michigan, Ann Arbor, Michigan
Michelle M. Schwedhelm
Affiliation:
Nebraska Medicine, Omaha, Nebraska
John J. Lowe
Affiliation:
University of Nebraska Medical Center, Omaha, Nebraska
*
Author for correspondence: Jocelyn J. Herstein, E-mail: jocelyn.herstein@unmc.edu
Rights & Permissions [Opens in a new window]

Abstract

Objective:

In response to the 2014–2016 West Africa Ebola virus disease (EVD) epidemic, the Centers for Disease Control and Prevention (CDC) designated 56 US hospitals as Ebola treatment centers (ETCs) with high-level isolation capabilities. We sought to determine the ongoing sustainability of ETCs and to identify how ETC capabilities have affected hospital, local, and regional coronavirus disease 2019 (COVID-19) readiness and response.

Design:

An electronic survey included both qualitative and quantitative questions and was structured into 2 sections: operational sustainability and role in the COVID-19 response.

Setting and participants:

The survey was distributed to site representatives from the 56 originally designated ETCs, and 37 (66%) responded.

Methods:

Data were coded and analyzed using descriptive statistics.

Results:

Of the 37 responding ETCs, 33 (89%) reported that they were still operating, and 4 had decommissioned. ETCs that maintain high-level isolation capabilities incurred a mean of $234,367 in expenses per year. All but 1 ETC reported that existing capabilities (eg, trained staff, infrastructure) before COVID-19 positively affected their hospital, local, and regional COVID-19 readiness and response (eg, ETC trained staff, donated supplies, and shared developed protocols).

Conclusions:

Existing high-level isolation capabilities and expertise developed following the 2014–2016 EVD epidemic were leveraged by ETCs to assist hospital-wide readiness for COVID-19 and to support responses by other local and regional hospitals However, ETCs face continued challenges in sustaining those capabilities for high-consequence infectious diseases.

Information

Type
Original Article
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Table 1. Geographic Distribution of Responding Ebola Treatment Centers (N = 37)a

Figure 1

Fig. 1. Role of Ebola treatment center (ETC) high-level isolation capabilities in hospital, local, and regional response to COVID-19, by percentage (N = 27). Note. PUI, patient under investigation; HLIU, high-level isolation; SME, subject-matter expert.

Figure 2

Fig. 2. Pre-existing high-level isolation capabilities that Ebola treatment centers (ETCs) perceived enhanced unit readiness and response to COVID-19, by percentage (N = 27). Note. PPE, personal protective equipment; NETEC, National Emerging Special Pathogens Training and Education Center.

Figure 3

Table 2. Reported Ways Ebola Treatment Centers Shared High-Level Isolation Capabilities With the Broader Hospital and Perception of How Those Capabilities Affected Overall Hospital-Wide Readiness and Response to COVID-19 (N=27)

Figure 4

Table 3. Reported Pre-existing High-Level Isolation Capabilities Ebola Treatment Centers Used or Did Not Use During the COVID-19 Pandemic Response, as of April 2021 (N = 29)

Figure 5

Table 4. Reported Lessons Learned and Innovative Practices Shared by Responding Ebola Treatment Centers (N = 29)

Supplementary material: PDF

Herstein et al. supplementary material

Herstein et al. supplementary material

Download Herstein et al. supplementary material(PDF)
PDF 143.2 KB